ACONW
HealthcareAclarion Inc - Warrants (01/12/2026)
$0.03+0.00 (+10.39%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ACONW Today?
No stock-specific AI insight has been generated for ACONW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$67,780
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume100
Avg Volume (10D)—
Shares Outstanding2.0M
ACONW News
20 articles- Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate EnrollmentYahoo Finance·May 7, 2026
- Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.Yahoo Finance·May 6, 2026
- Aclarion Announces Second Commercial Agreement with Weill Cornell MedicineYahoo Finance·May 5, 2026
- Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical AdoptionYahoo Finance·Apr 30, 2026
- Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of NociscanGlobeNewswire Inc.·Apr 28, 2026
- Aclarion Announces $2.5 Million Stock Repurchase PlanYahoo Finance·Apr 22, 2026
- Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back PainYahoo Finance·Apr 16, 2026
- Aclarion Receives Pinnacle Award for AI InnovationYahoo Finance·Apr 14, 2026
- Aclarion Announces Agreement with Weill Cornell MedicineYahoo Finance·Apr 8, 2026
- Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician VideoYahoo Finance·Apr 7, 2026
- Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.Yahoo Finance·Mar 24, 2026
- Aclarion, Inc. Adopts Limited Duration Stockholder Rights PlanYahoo Finance·Mar 19, 2026
- Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 CatalystsYahoo Finance·Mar 19, 2026
- Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance SheetYahoo Finance·Mar 17, 2026
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market ExpansionYahoo Finance·Nov 5, 2025
- Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTHYahoo Finance·Oct 22, 2025
- Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data CatalystYahoo Finance·Oct 14, 2025
- Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience ConferenceYahoo Finance·Oct 13, 2025
- Aclarion to Present at the LD Micro Main Event XIXYahoo Finance·Oct 9, 2025
- Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTHYahoo Finance·Oct 7, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.03
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$67,780
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume100
Avg Volume (10D)—
Shares Outstanding2.0M
About Aclarion Inc - Warrants (01/12/2026)
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
HealthcareSERVICES-MEDICAL LABORATORIES
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICSERVICES-MEDICAL LABORATORIES
CIK—
Composite FIGI—
Share Class FIGI—